

Table 3**Association between *XRCC1* and *XPB* genotypes and breast cancer risk according to smoking habits**

Genotype	Never active or passive smoking			Only passive smoking			Active smoking		
	Cases (%)	Controls (%)	OR (95% CI) ^a	Cases (%)	Controls (%)	OR (95% CI) ^a	Cases (%)	Controls (%)	OR (95% CI) ^a
<i>XRCC1</i> -280									
<i>Arg/Arg</i>	177 (84.7)	154 (84.6)	1.0	120 (79.5)	140 (83.8)	1.0	94 (83.9)	111 (86.0)	1.0
<i>Arg/His+His/His</i>	32 (15.3)	28 (15.4)	1.09 (0.60–1.99)	31 (20.5)	27 (16.2)	1.11 (0.59–2.08)	18 (16.1)	18 (14.0)	1.41 (0.65–3.08)
<i>XRCC1</i> -399									
<i>Arg/Arg</i>	118 (56.5)	89 (48.9)	1.0	72 (47.7)	91 (54.5)	1.0	45 (40.5)	75 (58.6)	1.0
<i>Arg/Gln</i>	76 (36.4)	76 (41.8)	0.83 (0.53–1.31)	67 (44.4)	66 (39.5)	1.40 (0.84–2.32)	49 (44.2)	43 (33.6)	2.14 (1.15–3.97)
<i>Gln/Gln</i>	15 (7.2)	17 (9.3)	0.73 (0.33–1.64)	12 (7.9)	10 (6.0)	1.61 (0.61–4.23)	17 (15.3)	10 (7.8)	3.27 (1.25–8.58) ^b
<i>Arg/Gln+Gln/Gln</i>	91 (43.5)	93 (51.1)	0.81 (0.53–1.25)	79 (52.3)	76 (45.5)	1.42 (0.87–2.32)	66 (59.5)	53 (41.4)	2.33 (1.30–4.19) ^c
<i>XPB</i> -751									
<i>Lys/Lys</i>	66 (31.6)	58 (31.9)	1.0	40 (26.3)	56 (33.3)	1.0	40 (35.7)	40 (31.0)	1.0
<i>Lys/Gln</i>	109 (52.2)	91 (50.0)	1.03 (0.63–1.66)	83 (54.6)	77 (45.8)	1.35 (0.78–2.34)	40 (35.7)	77 (45.8)	0.68 (0.35–1.33)
<i>Gln/Gln</i>	34 (16.3)	33 (18.1)	0.78 (0.40–1.49)	29 (19.1)	35 (20.8)	0.84 (0.41–1.69)	32 (28.6)	35 (20.8)	1.96 (0.89–4.32)
<i>Lys/Lys+Lys/Gln</i>	175 (83.7)	149 (81.9)	1.0	123 (80.9)	133 (79.2)	1.0	80 (71.4)	109 (84.5)	1.0
<i>Gln/Gln</i>	34 (16.3)	33 (18.1)	0.77 (0.43–1.39)	29 (19.1)	35 (20.8)	0.70 (0.38–1.29)	32 (28.6)	20 (15.5)	2.52 (1.27–5.03) ^d

^aOdds ratios (ORs) and confidence intervals (CIs) adjusted for age, age at menarche, age at first full term pregnancy, number of pregnancies, history of benign breast disease, first degree family history of breast cancer, waist-to-hip ratio and use of alcohol. ^b*p* for trend = 0.003. ^cInteraction between smoking habits and *XRCC1*-399 genotype (*p* = 0.025). ^dInteraction between smoking habits and *XPB*-751 genotype (*p* = 0.011).

95% CI 1.25–8.58, *p* for trend = 0.003) *XRCC1*-399 *Gln* variant alleles compared to those carrying the *Arg/Arg* genotype (*p* for interaction between smoking habits and *XRCC1*-399 genotype 0.025) (Table 3). A similar increase in risk was seen for ever smoking women with the *XPB*-751 *Gln/Gln* genotype compared to ever smoking women without this genotype (OR 2.52, 95% CI 1.27–5.03, *p* for interaction 0.011).

When ever smoking women were further stratified by pack-years smoked (<5, ≥5 pack-years), the increase in risk was seen to be confined to those who had smoked over five pack-years and carried at least one *XRCC1*-399 *Gln* allele (OR 4.14, 95% CI 1.66–10.3), or the *XPB*-751 *Gln/Gln* genotype (OR 4.41, 95% CI 1.62–12.0) compared to similarly smoking women without these genotypes (Table 4). Similar effects were seen for the *XRCC1* *Arg399Gln* genotypes when smokers were stratified by daily tobacco consumption (<10, ≥10 cigarettes/day) or by smoking years (<15, ≥15 years). The ORs were 5.32 (95% CI 1.97–14.4) for women smoking ≥10 cigarettes/day and carrying at least one *XRCC1*-399 *Gln* allele, and 4.03 (95% CI 1.40–11.6) for women who had smoked ≥15 years and carried at least one *XRCC1*-399 *Gln* allele, compared to women with similar smoking habits but with the *XRCC1*-399 *Arg/Arg* genotype. For the carriers of the *XPB*-751 *Gln/Gln* genotype, a similar increase in the risk of breast cancer was seen for women smoking ≥10 cigarettes/day (OR 4.78, 95% CI 1.50–15.2) while no statistically significant increase was seen by smoking years (OR 2.25, 95% CI

0.85–5.96 for women smoking ≥15 years), compared to women smoking the same amount, but not carrying the homozygous variant *XPB*-751 *Gln/Gln* genotype.

When stratified by current use of alcohol, women who reported using alcohol weekly to daily and carried the *XPB*-751 *Gln/Gln* genotype were at 3.18-fold (95% CI 1.34–7.57) increased risk of breast cancer compared to similarly drinking women carrying the other genotypes (*p* for interaction 0.026). No interaction was found between *XRCC1*-280 or *XRCC1*-399 genotypes and current use of alcohol (data not shown).

When the joint effect of the *XRCC1*-280, *XRCC1*-399, and *XPB*-751 genotypes was studied, a statistically significant increase in the risk of breast cancer was seen for subjects carrying two at-risk genotypes of these genes (OR 1.54, 95% CI 1.00–2.37) compared to subjects with the wild-type genotypes for all three polymorphic sites (Table 5). This increase was mainly due to the combined effect of *XRCC1*-399 and *XPB*-751 genotypes (OR 1.80, 95% CI 1.05–3.08, *p* for gene-gene interaction 0.043). A trend of increasing risk with increasing number of at-risk genotypes was seen (*p* for trend 0.042). However, this estimate did not reach statistical significance (OR 4.76, 95% CI 0.48–47.8), possibly due to the low number of subjects with all the three at-risk genotypes (four cases and one control). When the combined effects were studied among ever active smokers, women who carried any two at-risk genotypes were at remarkably increased risk of